---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-071928"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T22:50:49.771775+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.82
calibrated_materiality_score: 0.82
confidence: "high"
source: SEC EDGAR
---

# Madrigal in-licenses oral GLP-1 SYH2086 from CSPC for up to $2B in milestones

## Summary
- Upfront payment of $120M; potential milestone payments up to $2B plus royalties on net sales.
- Madrigal plans to start clinical development for SYH2086 in first half of 2026; deal expected to close Q4 2025.
- Aims to combine Rezdiffra (resmetirom) with oral GLP-1 for MASH, citing enhanced antifibrotic benefit with modest weight loss.
- CSPC retains rights to develop other oral GLP-1 agonists in China subject to conditions.

## SEC filing metadata
- accession: 0001104659-25-071928
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.82
- calibrated_materiality_score: 0.82
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000110465925071928/0001104659-25-071928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000110465925071928/tm2522007d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-071928
- JSON: https://secwatch.observer/filing/0001104659-25-071928.json
- Plain text: https://secwatch.observer/filing/0001104659-25-071928.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.